Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine

Ismael Artur da Costa-Rocha, Ana Carolina Campi‐Azevedo, Vanessa Peruhype-Magalhães, Jordana Grazziela Alves Coelho-dos-Reis, Jordana Rodrigues Barbosa Fradico, Thalles Souza-Lopes, Laise Rodrigues Reis, Larissa Chaves Freire, Christiane Costa-Pereira, Juliana Vaz de Melo Mambrini,

Frontiers in Immunology · 2019 · 18 citations · 17 references

DOIFull text

Open access

Concepts

Abstract

= 98) originally enrolled in the dose-response study in 2009 and 46 non-vaccinated controls. Our results demonstrated that vaccinees, who had seroconverted following primary vaccination and had not been revaccinated, present similar neutralizing antibodies levels and YF-specific cellular memory, particularly CMCD4 and EMCD8 as compared to the reference full dose (27,476IU). Although, PRNT seropositivity rates were similar across subgroups (94, 82, 83, 94, 80, and 91%, correspondingly), only doses above 587IU elicited similar iterative proportion of seropositivity rates, calculated as a progressive decrease on seropositivity rates along time (89, 80, 80, and 91%, respectively) as compared to 158IU and 31IU (68 and 46%, respectively). Noteworthy were the strong positive correlations ("EMCD4,EMCD8" and "TNFCD8,IFNCD8") observed in most subdoses, except for 31IU. Major similarities underscored the preserved antibody titers and the outstanding levels of EMCD8, relevant correlates of protection for YF-specific immunity. These findings provide evidences to support the regular use of dose sparing strategy for YF vaccine in adults.

References

17